#National Cancer Institute

The Moonshot has been achieving its intended goals and is rapidly advancing the science for a range of research priorities.

The National Cancer Institute answers some of your questions regarding the novel coronavirus.

“In the era of targeted therapy, it is critical to know that a therapy is the right choice and is going to be effective.”

“We are excited about these inhibitors and the potential for them to have an anticancer effect while also potentially preventing bone loss.�...

A month after receiving the treatment, there were higher levels of CAR T cells in the blood of patients who got the new therapy.

Numerous studies have identified access to care as a contributor to health-related disparities.

“This technology could help inform how aggressive or conservative surgery needs to be.”

The National Cancer Institute stands to lose more than $500 million, and cancer prevention programs are at risk.

Several NCI-funded randomized clinical trials comparing proton and traditional radiation therapy are currently ongoing.

This approval highlights a trend in cancer research, with drugs being designed for small, genetically defined populations of patients.

Researcher interview with Jason Locasale

The biological mechanisms responsible for the abscopal effect are still being investigated, but the immune system may play an big role.

Researchers hope these studies will provide new insights into ways of blocking the early stages of metastasis.

The drug may represent a “fundamental building block for new combinations that will hopefully have transformative potential.”

The American Cancer Society sets the record straight.

In both clinical trials, women whose cancers had spread to the brain were eligible to participate.